参展商

AD Check 認知測™ uses a breakthrough medical technology that has been clinically validated and recognized by the U.S. Food and Drug Administration (FDA) to accurately detect the levels of a biomarker related to Alzheimer’s Disease (AD) pathology in the blood: phosphorylated Tau217 protein (p-Tau217). This helps assess the risk of Alzheimer’s Disease (AD) pathology and allows for regular monitoring of risk changes as individuals age.Research further indicates that the testing technology used in AD Check 認知測™ is consistent with the results of traditional positron emission tomography (PET-Aβ, PET-Tau) and cerebrospinal fluid biomarkers (CSF Aβ42/40, and CSF p-Tau181).AD Check認知測™ accuracy reaches 96%, with a sensitivity of 98.2% and a specificity of 98.6%,test by local accredited laboratory.

Virtual Brain Technology (Free On-Site Trials Available May 16-18)Virtual Brain is the only product in Hong Kong that utilizes eye-tracking technology to accurately screen for the risk of brain degeneration and incorporates virtual reality technology for targeted brain degeneration therapy. This innovative smart product has been certified by the U.S. FDA and China's NMPA and is used as a medical-grade screening and treatment product. The virtual reality device automatically tracks eye movement trajectories, requiring no physical action from the user, and completes the screening in just 5 minutes. It can easily identify risks of mild cognitive impairment (MCI) and dementia with an accuracy rate of 78% - 91%. After the screening, AI automatically analyzes data from six cognitive areas of the user and recommends a tailored list of virtual reality game therapies. During the game therapy, AI analyzes user data and adjusts the difficulty in real-time, customizing it to achieve optimal training results.SMART solution for occupational therapy centers, community rehabilitation centers, and nursing homes.For more information, please contact:(852) 9711 9922

Discover Early Risks of Mild Cognitive Impairment (MCI) and Seize Early Treatment Opportunities to Delay Disease ProgressionBDR Technology Overview (Free On-Site Trials Available May 16-18)Electroencephalography (EEG) signals are one of the effective tools for diagnosing brain disorders. The BDR system is FDA approved in the United States and utilizes a 5-minute EEG collection followed by AI analysis to calculate the probabilities of normal and mild brain degeneration, continuously monitoring degenerative trends. This technology offers a non-invasive, convenient, safe screening process with clinical data validation, achieving an accuracy rate of 84%. BDR has successfully overcome the challenges of traditional methods in identifying early brain degeneration, representing an innovative application of medical technology in early screening. [2] Wijaya A, Setiawan NA, Ahmad AH, Zakaria R, Othman Z. Electroencephalography and mild cognitive impairment research: A scoping review and bibliometric analysis (ScoRBA). AIMS Neurosci. 2023 Jun 13;10(2):154-171. doi: 10.3934/Neuroscience.2023012. PMID: 37426780; PMCID: PMC10323261. Achieve Early and Accurate Assessment of Brain Degeneration Risk to Delay and Prevent Ongoing Deterioration!SMART solution for use by medical institutions and elderly care service organizations. For more information, please contact:(852) 9711 9922

Accurate, Objective Depression Risk Assessment,&nbsp;Effectively Assisting&nbsp;Clinical Psychological TreatmentSEA Technology Introduction (Free On-Site Trials Available May 16-18)The SEA system is the world's first system to analyze brainwave stress indices. This system is FDA approved in the US and utilizes a 5-minute collection of brain signals followed by AI analysis. It provides objective data assessment beyond self-perception and behavioral observation, displaying an intuitive stress data distribution chart to assist in discovering latent depression. This technology offers a non-invasive, convenient, safe screening process with clinical data validation, achieving an accuracy rate of 84%. It can assist experts or patients themselves in screening and monitoring conditions for treatment reference, complementing traditional diagnostic methods with meaningful innovative intelligent testing data. SMART solution for use by mental health communities/counseling centers and medical institutions.For more information, please contact:(852) 97119922

展会概览

参展商名单

产品目录

展览厅切面图

成功故事

展会场刊 2025

重要公布

展会资讯

申请展位

参展费用及形式

广告服务

中小企业市场推广基金

资讯中心

参展资讯

电子通讯

香港贸发局商贸平台APP及e-Badge

访客规则及法规

请小心处理由第三者提供之推广优惠

参观资讯

新闻稿

照片廊

展览视频

社交媒体/网络动态

合作媒体

新闻中心

传媒资讯

活动

香港的旅游签证和入境规例

办理中国内地入境签证及安排行程

特惠酒店

特惠机票

香港跨境现金管制措施

前往会场

Information for Muslim Visitors

畅游香港

恶劣天气的安排

访港资讯

查询

常见问题

贸发局活动

网上预先登记

合作媒体 2025

额外设施及服务申请表格

参展商手册

初次参展须知

参展费用及形式 2026

主页

通告

国泰航空机票优惠

与会人士快速过关安排

联系我们

绿色小贴士

穿梭巴士

卫生措施及健康资讯

社交媒体/网络动态 - 2021

社交媒体/网络动态 - 2019

社交媒体/网络动态 - 2018

社交媒体/网络动态 - 2017

社交媒体/网络动态 - 2016

Virtual Booths

Press Release

Agenda

活动及研讨会

保健护理世界

保健护理世界 - 一般资料

保健护理世界 - 联系我们

保健护理世界 - 概览

保健护理世界 - 展品类别介绍

社交媒体/网络动态 - 2022

展会资料下载

重要通告 (一)

社交媒体/网络动态 - 2024

Information for Muslim Visitors (只提供英文版本)